Johns Hopkins Medicine
  • Home
  • About Us
    • Click Here for
      Brady Centennial Anniversary


      The Brady Urological Institute, given through the generosity of James Buchanan Brady, opened January 21, 1915 and was the only one of its kind in the country.
      History
      Faculty Listing
      Faculty Directory
      Awards & Honors

      Video Resources

      urology history at jonhs hopkins
      Presented by Patrick Walsh, May 2013


      new discoveries in urology jonhs hopkins
      Discoveries in Urology: Past, Present and Future

      Books

      Autobiography of William Wallace Scott, Sr.

      Urology at Hopkins A Chronicle

      The Legacy of Hugh Hampton Young

      Hugh Young A Surgeon's Autobiography

      THE BRADY / 100years

  • Conditions & Treatments
    • Prostate

      Prostate Cancer
      Benign Prostate Hypertrophy

      Penis

      Peyronie's Disease
      Erectile Dysfunction

      Bladder

      Bladder Cancer
      Incontinence

      Ureter

      Ureteropelvic Junction Obstruction

      Kidney

      Kidney Cancer
      Kidney Stones

      Testis Cancer

      Genital Cancer

      MALE INFERTILITY

      GENITAL & PELVIC RECONSTRUCTION

      MINIMALLY INVASIVE SURGERY

      PEDIATRIC PATIENTS

  • Patient Care
    • Resources

      Appointments

      Referrals

      Find a Doctor

      Instructions For Patients

      Useful Links:

      Log into MyChart

      Accomodations

      Make a Gift
      What we treat                
  • Education
    • Residency

      Current Residents

      Applicants

      Alumni

      LOGIN

      Fellowships

      Urologic Oncology

      Minimally Invasive and Endourology

      Pediatric

      Sexual Medicine and Reconstructive

      Residency applicant interviews will be held on December 5 and December 12, 2017
      Please click here for more details.
  • Research
    • Research Laboratories

      Dr. Kenneth Pienta Laboratory

      URobotics

      Bladder Cancer Research Center

      Neuro-Urology Laboratory

      Veltri-Partin Fisher BIOMARKER RESEARCH LABORATORY

      Dr. Shawn Lupold Laboratory

      Keneth Pienta, M.D., Ph.D. - Hopkins Urology
      Kenneth J. Pienta, M.D.
      Director of Research
  • News & Events
  • Appointments
  • Contact
  • James Buchanan Brady Urological Institute
  • Clinical Trials
  • Audio/Video Resources
  • Newsletter
  • Make a Gift
  • Calendars
  •  
  •  
  •  
  •  
A PUBLICATION OF THE PATRICK C. WALSH PROSTATE CANCER RESEARCH FUND | THE BRADY UROLOGICAL INSTITUTE | JOHNS HOPKINS MEDICINE
  Download pdf        In this Issue        View Issues Archive

the patrick c. walsh prostate cancer research fund

Making Radiation More Effective: Breaking Cancer’s DNA

For men with localized but aggressive prostate cancer, combining radiation and androgen deprivation therapy (ADT) has been shown to make a big improvement in survival. This treatment is effective,” explains radiation oncologist Daniel Song, M.D., because of a double- whammy effect: “radiation breaks the cancer cell’s DNA, which can kill it, while hormones starve the cancer of its need for testosterone.”

Breaking the DNA strand makes the whole tumor more sensitive to radiation.

Another benefit of breaking the DNA strand: it makes the whole tumor more sensitive to radiation. “We have found that flutamide, a well-established drug that treats prostate cancer, can also produce DNA strand breaks,” Song continues. With co-principal investigators Srinivasan Yegnasubramanian, M.D., Ph.D., and Theodore DeWeese, M.D., Ph.D., “our strategy is to confirm these findings in men who have chosen to receive testosterone suppression and prostate brachytherapy,” or seed implant. In this project, men will be given a dose of flutamide before the procedure, and while they are already anesthetized for brachytherapy, they will undergo a prostate biopsy. “We will examine the biopsies to check for DNA strand breaks induced by flutamide, and if they are positive, we will move this work into a clinical trial for men with localized, aggressive prostate cancer.” Co-investigators are pathologists Angelo De Marzo, M.D., Ph.D., and Michael Haffner, M.D., and Jonathan Coulter, Ph.D., from the Department of Radiation Oncology.

 



© The James Buchanan Brady Urological Institute